SCHEMBL3084077

SCHEMBL3084077

CCOC(=O)C(Cc1cccc(Oc2ccc(F)cc2)c1)C(=O)N(CC)c1ccccc1

nearest known ligand 0.43

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
CETP P11597 5/20 0.43
NPY1R P25929 1/20 0.41
NPY2R P49146 1/20 0.41
MMP8 P22894 1/20 0.41
PPARG P37231 1/20 0.41
PPARA Q07869 1/20 0.41
TSHR P16473 1/20 0.40
MAPK1 P28482 1/20 0.40
TDP1 Q9NUW8 1/20 0.40
L3MBTL1 Q9Y468 1/20 0.40
ALDH1A1 P00352 1/20 0.40
TP53 P04637 1/20 0.40
CCR8 P51685 1/20 0.40
ALOX5 P09917 1/20 0.40
MME P08473 1/20 0.39
ACE P12821 1/20 0.39
CPA1 P15085 1/20 0.39
ACE2 Q9BYF1 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3089145 0.92 PPARG (0.46) CETPPPARGPPARAL3MBTL1ALDH1A1
SCHEMBL27787139 0.90 CETP (0.42) CETPTSHRMAPK1TDP1L3MBTL1
SCHEMBL3093454 0.85 NPY1R (0.49) NPY1RNPY2RMMP8PPARGTSHR
SCHEMBL27809161 0.84 FDFT1 (0.42) CETPPPARGPPARAL3MBTL1ALDH1A1
SCHEMBL5752575 0.81 MDM2 (0.50) CETPMMP8PPARGPPARATSHR
SCHEMBL9487640 0.81 MMP8 (0.56) MMP8PPARGPPARATSHRMAPK1
SCHEMBL3097023 0.80 SCN9A (0.40) CETPPPARGTSHRMAPK1ALDH1A1
SCHEMBL3097030 0.80 SCN9A (0.40) CETPPPARGTSHRMAPK1ALDH1A1
SCHEMBL3469623 0.77 PPARG (0.55) PPARGPPARAMMEACECPA1
SCHEMBL3092971 0.75 BCHE (0.50) TSHRALOX5MMEACECPA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2172450-B9 NOVEL MALONIC ACID SULFONAMIDE DERIVATIVE AND PHARMACEUTICAL USE THEREOF MITSUBISHI TANABE PHARMA CORP (JP) 2014-10-08 EP disclosed
EP-2172450-B1 NOVEL MALONIC ACID SULFONAMIDE DERIVATIVE AND PHARMACEUTICAL USE THEREOF MITSUBISHI TANABE PHARMA CORP (JP) 2013-10-16 EP disclosed
US-8461209-B2 Malonic acid sulfonamide derivative and pharmaceutical use thereof MITSUBISHI TANABE PHARMA CORPORATION (JP) 2013-06-11 US disclosed
US-20100228026-A1 NOVEL MALONIC ACID SULFONAMIDE DERIVATIVE AND PHARMACEUTICAL USE THEREOF MITSUBISHI TANABE PHARMA CORPORATION (JP) 2010-09-09 US disclosed
EP-2172450-A1 NOVEL MALONIC ACID SULFONAMIDE DERIVATIVE AND PHARMACEUTICAL USE THEREOF Mitsubishi Tanabe Pharma Corporation (JP) 2010-04-07 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100228026-A1 NOVEL MALONIC ACID SULFONAMIDE DERIVATIVE AND PHARMACEUTICAL USE THEREOF REN, AGTR2, AGTR1 CETP 3216/4885NPY1R 1344/4885NPY2R 1589/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.